SERES THERAPEUTICS INC (MCRB)
US81750R1023 - Common Stock
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream...
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that...
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that...
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple...
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics...
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced...
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Seres Therapeutics (NASDAQ:MCRB) just reported results for the second quarter o...
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September VOWST asset sale to provide $175M cash infusion, less...
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that...
Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity...
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
/PRNewswire/ -- Flagship Pioneering and ProFound™ Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines...
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics...
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
/PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health...
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025,...
Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management
Third research collaboration signed under strategic partnership between Novo Nordisk and Flagship Pioneering to develop novel treatment approaches for...
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative...